Compare EVO & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | AMLX |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2021 | 2022 |
| Metric | EVO | AMLX |
|---|---|---|
| Price | $3.20 | $11.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $7.00 | ★ $17.43 |
| AVG Volume (30 Days) | 250.1K | ★ 1.5M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $887,396,457.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.84 | $2.60 |
| 52 Week High | $4.80 | $16.96 |
| Indicator | EVO | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 54.56 | 31.05 |
| Support Level | $3.08 | $11.69 |
| Resistance Level | $3.18 | $12.80 |
| Average True Range (ATR) | 0.08 | 0.61 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 92.31 | 10.92 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.